Lenvatinib (off Label)
Lenvatinib + pembrolizumab
Eisai (investigator studies) · Phase 2 · Active, not recruiting · Enrollment 64
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| Lenvatinib + pembrolizumab | progressive R/M ACC (n = 17 evaluable) | not stated in source | Single arm | n/r | objective response rate: 6%, ASCO 2023 (search record) |